We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05382325
Recruitment Status : Recruiting
First Posted : May 19, 2022
Last Update Posted : October 21, 2022
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Brief Summary:
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Advanced or Metastatic Solid Tumors Biological: MK-1484 Biological: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors
Actual Study Start Date : June 16, 2022
Estimated Primary Completion Date : January 19, 2026
Estimated Study Completion Date : January 19, 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MK-1484
Participants will receive MK-1484 every 3 weeks (Q3W) or 21-day cycle at escalating dose levels from 0.2-60 mg for up to a total of 35 cycles (up to approximately 24 months).
Biological: MK-1484
Subcutaneous (SC) injection
Other Name: SP'482

Experimental: MK-1484 + Pembrolizumab
Participants will receive MK-1484 Q3W at escalating dose levels from 10-60 mg plus pembrolizumab 200 mg once every 21-day cycle for up to a total of 35 cycles (up to approximately 24 months).
Biological: MK-1484
Subcutaneous (SC) injection
Other Name: SP'482

Biological: Pembrolizumab
Intravenous (IV) infusion
Other Names:
  • MK-3475
  • Keytruda®




Primary Outcome Measures :
  1. Number of Participants with a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 5.0 [ Time Frame: Cycle 1 (Up to 21 days) ]
    DLT is defined as any of the following toxicities, if assessed by the investigator to be related to study treatment: Grade (Gr) 4 nonhematologic toxicity (not laboratory); Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia: Gr 4 thrombocytopenia of any duration; Gr 3 thrombocytopenia associated with clinically significant bleeding; Gr 4 anemia regardless of duration; Nonhematologic AE Gr ≥3 in severity, with exceptions; Any Gr 3 or 4 nonhematologic laboratory abnormality if: clinically significant medical intervention is required, or if abnormality leads to hospitalization, persists for >1 week or results in drug-induced liver injury with exceptions; Gr 3 or Gr 4 febrile neutropenia; Prolonged delay (>2 weeks) in initiating Cycle 2 due to treatment-related toxicity; Treatment-related toxicity resulting in participant study treatment discontinuation during Cycle 1; Missing >25% of the MK-1484 dose during Cycle 1 resulting from treatment-related AE; Gr 5 toxicity.

  2. Number of Participants Who Experience At Least One AE [ Time Frame: Up to approximately 27 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.

  3. Number of Participants Who Discontinue Study Treatment Due to an AE [ Time Frame: Up to approximately 24 months ]
    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE will be reported.


Secondary Outcome Measures :
  1. Area Under the Curve (AUC) of MK-1484 [ Time Frame: At designated time points (Up to approximately 24 months) ]
    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine AUC.

  2. Minimum Serum Concentration (Cmin) of MK-1484 [ Time Frame: At designated time points (Up to approximately 24 months) ]
    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmin.

  3. Maximum Serum Concentration (Cmax) of MK-1484 [ Time Frame: At designated time points (Up to approximately 24 months) ]
    Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

  • Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and has received, or been intolerant to, all treatment known to confer clinical benefit.
  • Has measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology.
  • Has normal cardiac function based on transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA)
  • Has provided an evaluable archival or newly obtained tumor tissue sample for biomarker analysis.
  • Has adequate organ function.
  • A male participant must agree to use contraception and should refrain from donating sperm during the specified period(s) of at least 120 days after study interventions.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following: not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the treatment period for at least 120 days after study intervention.

Exclusion Criteria:

  • Has and chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any AEs that were due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related AEs). Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study.
  • Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
  • Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody and/or components of the study interventions.
  • Has an active infection requiring therapy.
  • Has a history of interstitial lung disease.
  • Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy.
  • Participants with known human immunodeficiency virus (HIV) and/or hepatitis B or C infections, or known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus (HBV) DNA or hepatitis C Antibody or ribonucleic acid (RNA).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, make administration of the study drugs hazardous, or make it difficult to monitor adverse effects such that it is not in the best interest of the participant to participate.
  • Has known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Has not fully recovered from any effects of major surgery without significant detectable infection. Surgeries that required general anesthesia must be completed at least 2 weeks before first study intervention administration. Surgery requiring regional/epidural anesthesia must be completed at least 72 hours before first study intervention administration and participants should be recovered.
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the start of study treatment.
  • Has had an allogeneic tissue/solid organ transplant in the last 5 years or has evidence of graft-versus-host disease.
  • Has received any prior interleukin-2 (IL-2) based therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05382325


Contacts
Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com

Locations
Layout table for location information
United States, South Dakota
Sanford Cancer Center ( Site 0005) Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Study Coordinator    605-328-8000      
United States, Texas
NEXT Oncology ( Site 0001) Recruiting
San Antonio, Texas, United States, 78229
Contact: Study Coordinator    210-580-9500      
Canada, Ontario
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Study Coordinator    416 586 5371      
Israel
Rambam Health Care Campus-Oncology ( Site 0021) Recruiting
Haifa, Israel, 3109601
Contact: Study Coordinator    +972535316961      
Sheba Medical Center-ONCOLOGY ( Site 0020) Recruiting
Ramat Gan, Israel, 5265601
Contact: Study Coordinator    +97235302542      
Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) ( Site 0035) Recruiting
Amsterdam, Noord-Holland, Netherlands, 1066 CX
Contact: Study Coordinator    31205129111      
Erasmus Medisch Centrum-Medical Oncology ( Site 0036) Recruiting
Rotterdam, Zuid-Holland, Netherlands, 3015 GD
Contact: Study Coordinator    +31205662096      
Sponsors and Collaborators
Merck Sharp & Dohme LLC
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme LLC
Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT05382325    
Other Study ID Numbers: 1484-001
MK-1484-001 ( Other Identifier: Merck )
2021-005220-38 ( EudraCT Number )
First Posted: May 19, 2022    Key Record Dates
Last Update Posted: October 21, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Merck Sharp & Dohme LLC:
Programmed Cell Death-1 (PD1, PD-1)
Programmed Death-Ligand 1 (PDL1, PD-L1)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents